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Neuroleptic malignant 
syndrome: a case report 
and discussion
ABSTRACT
Neuroleptic malignant syndrome (NMS) is an emergent, life threatening condition most often seen as an iatrogenic compli-
cation of neuroleptic or antipsychotic treatment. It is characterized by a tetrad of clinical features: mental status changes, 
fever, muscle rigidity and autonomic instability, although it is not necessary for all of them to be present at a same time for 
working diagnosis to be made. This paper will deal with the case of a 29-year old male patient diagnosed with schizophrenia 
who developed NMS, presented as a generalized tonic-clonic seizure and high fever, after 191 days of in-hospital treatment. 
After 13 days of hospital treatment in the Intensive Care Unit of Clinical Hospital Dubrava, the patient is in a hemodynamical 
and proper quantitative mental state and discharged for further psychiatric treatment at his parent hospital institution. 
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Case report 
After 191 days of in-hospital treatment, 
a 29 year old male patient is transferred 
from a psychiatric institution to our 
Emergency Department (ED) under a 
working diagnosis of epileptic status. 
According to his medical history, he 
was a former intravenous drug addict 
with diagnosed schizophrenic disor-
der and chronic bronchitis. He was 
treated with clozapine (500mg divided 
into 3 daily doses), fluphenazine (5mg 
twice a day), with a depot formulation 
of fluphenazine (25mg intramuscularly) 
and biperiden (from 5mg), lorazepam 
(7.5mg orally divided into 3 daily doses) 
and nitrazepam (5mg once daily). The 
patient was conscious, psychomotori-
cally agitated, non-verbal, febrile 38.4 
°C, mild tachycardic with 1500 ml of 
urine retention. Other neurological and 
general physical statuses were incon-
spicuous. With brain imaging studies 
we excluded acute intracranial events, 
and with lumbar puncture we exclu-
ded a central nervous system infection. 
With regard to the fever, high creatine 
phosphokinase (CPK), significant hypo-
natremia and a history of treatment with 
antipsychotics, a working diagnosis of 
NMS was set and the patient was admi-
tted to the ICU 8 hours after his initial 
loss of consciousness. The initial labo-
ratory results showed: CPK 6308 IU/L, 
CPK MB 70 IU/L sodium 113 mEq/L , 
potassium 3.7 mEq/L, mildly elevated 
transaminases, leukocytosis 10,700/
mm3 , Hgb 12.8 g/dL, with other rou-
tinely used tests in a reference range. 
Immediately upon admission, psychi-
atric treatment was discontinued, the 
patient was sedated with the continuous 
intravenous administration of midazo-
lam. Supportive measures, including 
heavy intravenous administration of iso-
tonic crystalloid solution with electrolyte 
recovery and antipyretics with extra-
corporeal cooling measures, were also 
initiated. Over the next few days high 
CPK values were detected, with a maxi-
mum value of 323,400 IU/L detected 24 
hours after the onset of symptoms.  The 
patient’s myoglobin value was 8130 ng/
mL, and an increase in inflammatory 
parameters (CPR 179.5 mg/L, L 11,200/
mm3) along with high fever was noted. 
On day four, the patient became afebri-
le, sedation therapy was discontinued, 
the patient regained consciousness and 
vital parameters were normal, but the 
patient was still without adequate verbal 
contact, responding to painful stimuli 
with disapproval. On day eight, the pati-
ent became febrile again, his axillary 
temperature measured up to 39.4 °C 
with profuse sweating and hypersali-
vation and there was a minor increase 
in CPK and myoglobin. Samples were 
taken for blood and urine culture (later 
the cultures were sterile) and an empi-
rical antibiotic therapy with ciprofloxacin 
at a dose of 400 mg intravenously 2x1 
was initiated. The next day the patient 
became afebrile, with normal vital functi-
ons and established verbal contact. The 
patient’s further course of stay passed 
without additional complications and 
the patient was in a proper quantitative 
mental state, in good general condition, 
hemodynamically stable and was disc-
harged on day 13 for further treatment 
at his parent institution.
Discussion 
The incidence of NMS varies between 
0.02-3% of patients on neuroleptic the-
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rapy. (1) Cases have been described 
in all age groups, but among the cases 
described men of younger age were 
predominant. Factors that increase the 
risk of developing NMS are high doses 
of neuroleptic drugs, parenteral admi-
nistration, depot preparations, parallel 
treatment with lithium or other psycho-
tropic drugs, alcohol abuse, addiction 
and other acute diseases. (2) Assump-
tions about a genetic predisposition 
for developing NMS are suggested. 
(3) The main clinical features make the 
tetrad of symptoms: change in mental 
status, muscle rigidity, hyperthermia 
and autonomic dysfunction in terms of 
tachycardia, blood pressure variability, 
tachypnea and diaphoresis. (4) In an 
analysis of 340 cases of NMS, 70% 
of patients followed a typical pattern 
of symptoms with the altered men-
tal status change as the initial symp-
tom, followed by muscle rigidity, then 
hyperthermia and dysfunction of the 
autonomic nervous system occurring 
last. (5) The most important laboratory 
parameter is high CPK (> 1000 IU/L 
). (6) Leukocytosis is a consistent fin-
ding, and there are mild elevations in 
LDH and transaminases, electrolyte 
imbalance and myoglobinemia with 
the possibility of myoglobinuric acute 
renal failure. Atypical NMS cases, wit-
hout developing muscle rigidity, as 
well as afebrile cases, also exist. (7) 
In differential diagnosis, a physician 
should think of neurological disea-
ses such as infections of the central 
nervous system, convulsions within 
epilepsy or acute intracranial proce-
ss, acute intoxication, heat stroke and 
tetanus. Diagnosis is clinically made. 
In 2011, diagnostic criteria for NMS 
were published (table 1). (8) Treatment 
consists of neuroleptic therapy dis-
continuation and further supportive 
therapy. Of the specific measures, 
dantrolene, bromocriptine and aman-
tadine can be used. Clinical studies on 
the use of these drugs have not been 
implemented, and recommendations 
are based on the cases described in 
the literature. In most cases applied 
therapy leads to a regression of the 
disease within 14 days of the onset of 
symptoms. (4) Overall mortality ranges 
from 5-20%. Developing complications 
are the strongest predictor of mortality. 
Re-initiation of neuroleptic therapy is 
not contraindicated in recovered pati-
ents, but great caution is necessary 
regarding recurrent cases described 
in the literature. (9)
Conclusion
In our case a positive clinical outcome 
resulted by using only supportive the-
rapeutic measures thanks to a timely 
recognition of the disease. Given the 
relatively rare incidence of the disease 
and insufficient literature (lack of clinical 
studies and the lack of clear treatment 
guidelines) this life threatening condi-
tion is still represented by high values 
of mortality (20%). We emphasize the 
Table 1: Neuroleptic malignant syndrome diagnostic criteria.
Diagnostic criteria Priority score
Exposure to dopamine antagonist or dopamine agonist withdrawal within past 72 h 20
Hyperthermia (>100.4 º F or >38 º C on at least 2 occasions, measured orally) 18
Rigidity 17
Mental status alteration (reduced of fluctuating level of consciousness) 13
Creatinine kinase elevation (at least 4 times the upper limit of normal) 10
Sympathetic nervous system lability, defined as at least 2 of the following:
Blood pressure elevation (systolic or diastolic ≥ 25% above baseline)




Hypermetabolism defined as heart rate increase (≥ 25% above baseline) and respiratory rate 
increase (≥ 50% above baseline)
5
Negative work-up for infections, toxic, metabolic or neurologic causes 7
Total 100
Table 2: Generalized guidelines on restarting neuroleptic therapy
Wait at least 2 weeks before resuming therapy, longer if any clinical residua exist
Use lower rather than higher potency agents
Start with low doses and titrate upward slowly
Avoid concomitant lithium
Avoid dehydration and carefully monitor for symptoms of NMS
NMS, neuroleptic malignant syndrome
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necessity for early diagnosis to prevent 
further complications and  the impor-
tance of placing timely doubt in high-
risk patients, Regarding the possibility 
of regression and the need for further 
treatment of the underlying disease, to 
reduce the risk of relapse we emphasi-
ze the need to follow the general recom-
mendations summarized in table 2.
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